Skip to main content
SpringerLink
Log in

National Cancer Institute Experience with Regional Therapy for Unresectable Primary and Metastatic Cancer of the Liver or Peritoneal Cavity

  • Chapter
Regional Chemotherapy

Part of the book series: Current Clinical Oncology ((CCO))

Abstract

Patients who have unresectable primary or metastatic cancers of the liver or peritoneal carcinomatosis are rarely curable. The large number of regional treatments for the liver or peritoneal cavity that are under clinical evaluation underscore the difficulty in treating these conditions. In general, the rationale for regional therapies to intensify therapy, while minimizing unnecessary systemic toxicity, has been well established (1–3). Over the past 6 yr, regional treatment protocols, using specialized surgical techniques to deliver regional therapy to the peritoneal cavity or liver, have been under clinical evaluation in the Surgery Branch of the National Cancer Institute (NCI). These include isolated hepatic perfusion (IHP) for the treatment of unresectable primary or metastatic cancers confined to the liver, and continuous hyperthermic peritoneal perfusion (CHPP) for the treatment of, or prophylaxis against, peritoneal carcinomatosis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Dedrick RL. Theoretical and experimental bases of intraperitoneal chemotherapy, Semin. Oncol., 12 (1985) 1–6.

    PubMed  CAS  Google Scholar 

  2. Markman M. Intraperitoneal `Belly Bath’ chemotherapy, In T. Lokich (ed), Cancer Chemotherapy by Infusion, 1990, pp. 552–574.

    Google Scholar 

  3. Alexander HR, Bartlett DL, Fraker DL, and Libutti SK. Regional treatment strategies for unresectable primary or metastatic cancer confined to the liver, PPO Updates, Lippincott, Philadelphia, 10 (1996) 1–19.

    CAS  Google Scholar 

  4. Ausman RK. Development of a technic for isolated perfusion of the liver, NY State J. Med., 61 (1961) 3393–3397.

    Google Scholar 

  5. Aigner KR, Walther H, Tonn JC, Link KH, Schoch P, and Schwemmle K. Die isolierte leberperfusion bei fortgeschrittenen metastasen kolorektaler karzinome, Onkologie, 7 (1984) 13–21.

    Article  PubMed  CAS  Google Scholar 

  6. Aigner K, Walther H, Tonn J, et al. First experimental and clinical results of isolated liver perfusion with cytotoxics in metastases from colorectal primary, Recent Results Cancer Res., 86 (1983) 99–102.

    Article  PubMed  CAS  Google Scholar 

  7. Skibba JL and Quebbeman EJ. Tumoricidal effects and patient survival after hyperthermic liver perfusion, Arch. Surg.,121 (1986) 1266–1271.

    Google Scholar 

  8. Skibba JL, Quebbeman El, Komorowski RA, and Thorsen KM. Clinical results of hyperthermic liver perfusion for cancer in the liver, In KR Aigner, et al. (eds), Regional Cancer Treatment, Karger, Basel, 1988, pp. 222–228.

    Google Scholar 

  9. Schwemmle K, Link KH, and Rieck B. Rationale and indications for perfusion in liver tumors: current data, World J. Surg., 11 (1987) 534–540.

    Article  PubMed  CAS  Google Scholar 

  10. Hafström LR, Holmberg SB, Naredi PJ, et al. Isolated hyperthermic liver perfusion with chemotherapy for liver malignancy, Surg. Oncol., 3 (1994) 103–108.

    Article  PubMed  Google Scholar 

  11. Marinelli A, de Brauw LM, Beerman H, et al. Isolated liver perfusion with mitomycin C in the treatment of colorectal cancer metastases confined to the liver, Jpn. J. Clin. Oncol., 26 (1996) 341–350.

    Article  PubMed  CAS  Google Scholar 

  12. van Zuidewign DBW, de Brauw LM, Marinelli A, Keijzer HJ, van Bockel JH, and Van de Velde CJH. Isolated liver perfusion with mitomycin-C or melphalan in patients with hepatic metastases, Soc. Surg. Oncol., 46 (1993) 198 (Abstract).

    Google Scholar 

  13. Dudar TE and Jain RK. Differential response of normal and tumor microcirculation to hyperthermia, Cancer Res., 44 (1984) 605–612.

    Google Scholar 

  14. Cavaliere R, Ciogatto EC, Giovanelli BC, et al. Selective heat sensitivity of cancer cells, Cancer, 20 (1967) 1351–1387.

    Article  PubMed  CAS  Google Scholar 

  15. Buell JF, Reed E, Lee KB, et al. Synergistic effect and possible mechanisms of tumor necrosis factor and cisplatin cytotoxicity under moderate hyperthermia against gastric cancer cells, Ann. Surg. Oncol., 4 (1997) 141–148.

    Article  PubMed  CAS  Google Scholar 

  16. Klostergaard J, Leroux E, Siddik ZH, Khodadadian M, and Tomasovic SP Enhanced sensitivity of human colon tumor cell lines in vitro in response to thermochemoimmunotherapy, Cancer Res., 52 (1992) 5271–5277.

    PubMed  CAS  Google Scholar 

  17. Lienard D, Ewalenko P, Delmotte JJ, Renard N, and Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma, J. Clin. Oncol., 10 (1992) 52–60.

    PubMed  CAS  Google Scholar 

  18. Alexander HR, Fraker DL, and Bartlett DL. Isolated limb perfusion for malignant melanoma, Semin. Surg. Oncol., 12 (1996) 416–428.

    Article  PubMed  Google Scholar 

  19. Fraker DL, Alexander HR, Andrich M, and Rosenberg SA. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon-gamma: results of a TNF dose escalation study, J. Clin. Oncol., 14 (1996) 479–489.

    PubMed  CAS  Google Scholar 

  20. Eggermont AMM, Koops HS, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas, Ann. Surg., 224 (1996) 756–765.

    Article  PubMed  CAS  Google Scholar 

  21. Diebel LN, Wilson RF, Bender J, and Paules B. Comparison of passive and active shunting for bypass of the retrohepatic IVC, J. Trauma, 31 (1991) 987–990.

    Article  PubMed  CAS  Google Scholar 

  22. BarkerWC, Andrich MP, Alexander HR and Fraker DL. Continuous intraoperative external monitoring of perfusate leak using I-131 human serum albumin during isolated perfusion of the liver and limbs, Eur. J. Nucl. Med.,22 (1995) 1242–1248.

    Google Scholar 

  23. Fraker DL, Alexander HR, Bartlett DL, and Rosenberg SA. Prospective randomized trial of therapeutic isolated limb perfusion (ILP) comparing melphalan (M) versus melphalan, tumor necrosis factor (TNF) and interferon-gamma (IFN): an initial report, Soc. Surg. Oncol., 49 (1996) 6, (Abstract).

    Google Scholar 

  24. Posner MC, Lienard D, Lejeune FJ, Rosenfelder D, and Kirkwood J. Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma, Cancer J. Sci. Am., 1 (1995) 274–280.

    PubMed  CAS  Google Scholar 

  25. Leyvraz S, Spataro V, Bauer J, et al. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy, J. Clin. Oncol., 15 (1997) 2589–2595.

    PubMed  CAS  Google Scholar 

  26. Alexander HR, Buell JF, and Fraker DL. Rationale and clinical status of continuous hyperthermic peritoneal perfusion for the treatment of peritoneal carcinomatosis, In DeVita VT Jr, Hellman S, and Rosenberg SA (eds), Principles and Practice of Oncology: PPO updates. Lippincott, Philadelphia, 1995, pp. 1–9.

    Google Scholar 

  27. Spratt JS, Adcock RA, Muskovin M, Sherrill W, and McKeown J. Clinical delivery system for intraperitoneal hyperthermic chemotherapy, Cancer Res., 40 (1980) 256–260.

    PubMed  CAS  Google Scholar 

  28. Koga S, Hamazoe R, Maeta M, Shimizu N, Murakami A, and Wakatsuki T. Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C, Cancer, 61 (1988) 232–237.

    Article  PubMed  CAS  Google Scholar 

  29. Fujimoto S, Shrestha RD, Kokuban M, et al. Positive results of combined therapy of surgery and intraperitoneal hyperthermic perfusion for far-advanced gastric cancer, Ann. Surg.,212 (1990) 592596.

    Google Scholar 

  30. Fujimura T, Yonemura Y, Fushida S, et al. Continuous hyperthermic peritoneal perfusion for the treatment of peritoneal dissemination in gastric cancers and subsequent second-look operation, Cancer, 65 (1990) 65–71.

    Article  PubMed  CAS  Google Scholar 

  31. Fujimura T, Yonemura Y, Muraoka K, et al. Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: randomized controlled study, World J. Surg., 18 (1994) 150–155.

    Article  PubMed  CAS  Google Scholar 

  32. Hamazoe R, Maeta M, and Kaibara N. Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer, Cancer, 73 (1994) 2048–2052.

    Article  PubMed  CAS  Google Scholar 

  33. Fujimoto S, Shrestha RD, Kokubun M, et al. Pharmacokinetic analysis of mitomycin C for intraperitoneal hyperthermic perfusion in patients with far-advanced or recurrent gastric cancer, Reg. Cancer Treat., 2 (1989) 198–202.

    Google Scholar 

  34. Gilly FN, Carry PY, Sayag AC, et al. Regional chemotherapy (with mitomycin C) and intraoperative hyperthermia for digestive cancers with peritoneal carcinomatosis, Hepato-gastroenterology,41 (1994) 124–129.

    Google Scholar 

  35. Dikhoff T, van der Heider J, Dubbelman R, and ten Bokkel Huinink WW. Tissue concentration of platinum after intraperitoneal cisplatin administration in patients, Proc. AACR, 26 (1985) 162.

    Google Scholar 

  36. Howell SB, Pfeifle CG, Wung WE, et al. Intraperitoneal cisplatin with systemic thiosulfate protection, Ann. Intern. Med., 97 (1982) 845–851.

    Article  PubMed  CAS  Google Scholar 

  37. Flessner MF and Dedrick RL. Intraperitoneal chemotherapy, In Gokal R and Nolph KD (eds), Textbook of Peritoneal Dialysis. Kluwer, The Netherlands, 1994, pp. 769–789.

    Chapter  Google Scholar 

  38. Kitamura K, Kuwano H, Matsuda H, Toh Y, Masuda H, and Sugimachi K. Synergistic effects of intratumor administration of cis-diamminedichloroplatinum(II) combined with local hyperthermia in melanoma bearing mice, J. Surg. Oncol., 51 (1992) 188–194.

    Article  PubMed  CAS  Google Scholar 

  39. Alexander HR, Bartlett DL, and Libutti SK. Isolated hepatic perfusion: A potentially effective treatment for patients with metastatic or primary cancers confined to the liver, Cancer J. Sci. Amer., 4 (1998) 2–11.

    Google Scholar 

  40. Bartlett DL, Buell JF, Libutti SK, et al. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis, Cancer, 83 (1998) 1251–1261.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. H. Richard Alexander
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David L. Bartlett
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Steven K. Libutti
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Cleveland Clinic Taussig Cancer Center, Department of Hematology/Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH, USA

    Maurie Markman MD (Director, Chairman) (Director, Chairman)

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Science+Business Media New York

About this chapter

Cite this chapter

Alexander, H.R., Bartlett, D.L., Libutti, S.K. (2000). National Cancer Institute Experience with Regional Therapy for Unresectable Primary and Metastatic Cancer of the Liver or Peritoneal Cavity. In: Markman, M. (eds) Regional Chemotherapy. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-219-7_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-219-7_8

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4684-9697-0

  • Online ISBN: 978-1-59259-219-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation